Web4 Apr 2024 · On April 4, Scorpion Therapeutics announced a collaboration and license agreement with the French dermo-cosmetic and pharmaceutical group Pierre Fabre to codevelop two next-generation epidermal growth factor receptor (EGFR) inhibitors.. STX-241 and STX-721, both target EGFR mutations in non-small cell lung cancer (NSCLC). More … Web4 Dec 2024 · Recommend. CEO Approval. Business Outlook. Pros. Data platform is one of the best in industry, talent is top tier, leadership is strong/aproachable, and lots of opportunity to grow and develop. Cons. Still a pre-IPO biotech start-up with lean teams. Def going through growing pains but will get better over time.
Scorpion Therapeutics Jobs & Careers - 28 Open Positions
Web26 Oct 2024 · We are developing drugs specifically designed to interact with validated cancer targets with greater selectivity and optimized pharmaceutical properties to … Our fully integrated discovery platform is built upon the most advanced … Scorpion. Great culture and community, paired with our depth of knowledge, has … Driven by advances in cancer biology, medicinal chemistry and data sciences … Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License … Address. 2 Tower Place 3rd Floor South San Francisco, Phone. 781-288-5760. Contact … Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License … Web3 Apr 2024 · BOSTON--(BUSINESS WIRE)-- Scorpion Therapeutics, Inc. (“Scorpion”), a clinical-stage biotechnology company redefining the frontier of precision medicine through its Precision Oncology 2.0 strategy, today announced that it has named STX-241 as its next development candidate.STX-241 is the third development candidate nominated by … hcrg care group sittingbourne
Serial entrepreneur, former IFM CEO launches immuno-oncology startup
WebScorpion Therapeutics is building its pipeline in three distinct tracks: the first is focused on designing best- or first-in-class therapeutic candidates against known, high-impact … WebDr. Walmsley serves as General Partner of Logos Capital and co-manages the firm’s private efforts. Prior to Logos, Dr. Walmsley was a Principal and Manager of the crossover fund at Versant Ventures where he invested in biotechnology companies across multiple funds totaling over $1.5 billion in AUM. Web13 Jan 2024 · AstraZeneca has signed a collaboration agreement with Scorpion Therapeutics to discover, develop and commercialise precision medicines against … goldees all purpose rub